China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 1, 2023.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the third quarter and first nine months of 2023.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Werfen announced recently that its subsidiary Inova Diagnostics has secured US Food and Drug Administration 510(k) clearance for a blood-based immunoassay reagent used to aid the diagnosis of connective tissue diseases.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2023.

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2023.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2023.

Abbott's RealTime IDH1 Assay has received approval from the US Food and Drug Administration as a companion diagnostic for Servier Pharmaceuticals' Tibsovo (ivosidenib) in patients with relapsed or refractory myelodysplastic syndrome, the FDA announced on Tuesday.

Shares of Thermo Fisher Scientific (TMO) slumped over 7% in early trading Wednesday after the maker of lab equipment and analytical instruments posted weaker-than-expected sales and cut its outlook for a second-straight quarter on slowing demand.

Listed companies with main IVD business in China have completed the disclosure of their financial results in the first half of 2023.

Quest Diagnostics Inc (DGX, Financial), a leading provider of diagnostic information services, released its Q3 2023 earnings report on October 24, 2023. Despite a decrease in overall revenues, the company's base business revenues showed growth, largely due to strength in their physician and hospital channels.

On October 24, 2023, Danaher Corp (DHR, Financial) released its Q3 2023 earnings report, revealing a net earnings of $1.1 billion, or $1.51 per diluted common share.

Foundation Medicine announced on Monday that it is expanding its partnership with Sequanta Technologies to provide its genomic profiling tests for research and oncology therapy development in China.

Switzerland's Roche (ROG.S) has agreed to pay an initial $7.1 billion to Roivant (ROIV.O) and Pfizer (PFE.N) for rights to a new inflammatory bowel disease drug, as it expands into new fields to offset falling oncology sales.